MHQ: Clinical IntelligencePowered by SurvivorNet

Health Panel
Clinical Trials

?

Prefer to talk instead of typing?

Answers offered are informational and do not constitute medical advice. Learn more

Health Profile

Enter health info to personalize results.

What is your gender?

What is your age?

Clinical Trials

Clear List

Sign In

Prostate Cancer

Dr. Daniel Spratt On Rethinking Frontline Strategy in High-Risk Prostate Cancer: Why Radioligand Therapy May Belong Earlier

SurvivorNet Staff

Dr. Daniel Spratt On The Future Of Radioligands For Prostate Cancer: Balancing Toxicity With Quality Of Life

Jayson Haedrich,

–

Genitourinary Cancers

Dr. Spratt On What’s Next For Radioligands: Combination With External Beam Radiation, Managing Payload And Alternative Targets

Jayson Haedrich,

–

Genitourinary Cancers

Adding PARP Inhibitor Niraparib To Standard Improves Outcomes For Advanced Prostate Cancer With HRR Gene Mutation

Genitourinary Cancers

A Potential Game-Changer in Prostate Cancer: A Simple Genomic Test Can Tell Us Who Needs Hormone Therapy And Who Doesn’t

Dr. Rodrigo C. Leão Edelmuth

Genitourinary Cancers

Men with Prostate Cancer Are Asking Their Doctors About Rectal Spacers

Dr. James Taylor,

National Cancer Institute

Genitourinary Cancers

Integrating Genetic Testing and PARP Inhibitors in Prostate Cancer Management

Dr. Rodrigo C. Leão Edelmuth

Oxybutynin Shows Clinically Meaningful Benefit For ADT-Associated Hot Flashes In Prostate Cancer

Dr. Rodrigo C. Leão Edelmuth

Understanding Pluvicto (Lutetium-177) and PSMA PET Scans in Prostate Cancer Treatment

Dr. Rodrigo C. Leão Edelmuth